Press releases
- Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
- Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
- Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
- Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
- Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
- Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
- Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
More ▼
Key statistics
As of last trade Arrowhead Pharmaceuticals Inc (HDP1:MUN) traded at 22.47, 2.14% above its 52-week low of 22.00, set on Mar 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.47 |
---|---|
High | 22.47 |
Low | 22.47 |
Bid | 22.38 |
Offer | 22.53 |
Previous close | 22.47 |
Average volume | 14.60 |
---|---|
Shares outstanding | 108.31m |
Free float | 103.29m |
P/E (TTM) | -- |
Market cap | 2.63bn USD |
EPS (TTM) | -1.47 USD |
Data delayed at least 15 minutes, as of Mar 29 2023 07:01 BST.
More ▼